CDK4 and aneurysmal bone cyst: However, due to a fast-changing treatment landscape and extraordinary results from novel anti-HER2 therapies, such as trastuzumab-deruxtecan and tucatinib [82], late-phase trials with CDK4/6i for HER2-positive aBC are not being performed for every CDK4/6i.